AstraZeneca Streptase AEs Increase With Reduced Abbokinase Availability
Executive Summary
Suspended distribution of Abbott's thrombolytic agent Abbokinase may be contributing to increases in adverse events associated with off-label use of AstraZeneca's Streptase, AstraZeneca said in a recent "Dear Healthcare Professional" letter.